Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaChronic Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupICD10C91.0-C92.0-C92.1-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceChemotherapyChemo-substanceAzacitidineCyclophosphamideLenalidomideChemo-substanceAzacitidineCyclophosphamideLenalidomideChemo-substanceAzacitidineCyclophosphamideLenalidomideChemo-substanceAzacitidineCyclophosphamideLenalidomideNo. Substances12 RadiotherapySupportive therapySupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances3101112131416Protocol classificationTherapy classificationalternativecurrent standardIntensityHochdosis, bei autologer SZTKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Konditionierung, nicht-myeloablativ (NMA)Standard doseTherapy indicationFirst lineRelapse therapyTherapy phaseallogene Stammzelltransplantationautologous stem cell transplantationTherapy intentioncurativecurative or palliativepalliativeRisksBleedingCardiotoxicityEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHyperbilirubinemiaInfectionsNeurotoxicityNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBeelen DWBlume KGCiurea SOCraddock CDusenbery KEEstey EKornblit BLee JHLübbert MMarks RPlatzbecker URambaldi ASanz JSchroeder TShimoni AStölzel FDiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, auto-SZTAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML, über 50 J.AML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/ALL/CML, allogene StammzelltransplantationAML/MDS, 15-70 Jahre, mit HLA-identischem oder an einem Locus nicht übereinstimmender Geschwister-, Familien- oder nicht verwandtem SpenderAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, ALL, allogene StammzelltransplantationAML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)OriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyAsan Medical Center, University of Ulsan College of Medicine, SeoulCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialCity of Hope National Medical Center, California, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WashingtonDepartment of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDepartment of Therapeutic Radiology, University of Minnesota Hospital and Clinics, MinneapolisDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyHospital Universitari i Politecnic La Fe, Valencia, SpainOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyThe Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUniversity Hospital Schleswig-Holstein, Kiel, Christian Albrechts University, Kiel, GermanyUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 17 protocols foundAzacitidine 100, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation, Variant 1 (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome following Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2327 V1.0)Revision: Busulfan 3.2 / Cyclophosphamide 60, Allogeneic Stem Cell Transplantation, MAC (PID882 V1.1)Busulfan 3.2 / Etoposide 20 / Cytarabine 3000, Autologous Stem Cell Transplantation (PID3250 V1.0)Cyclophosphamide 60 / TBI 13.2, Allogeneic Stem Cell Transplantation, MAC (PID3218 V1.0)Etoposide Phosphate 60 / TBI 13.2, Allogeneic Stem Cell Transplantation, MAC (PID3221 V1.0)Fludarabine 30 / Busulfan 3.2, Acute Myeloid Leukemia, Stem Cell Transplantation, Allogeneic (PID3226 V1.0)Fludarabine 30 / Carmustine 150 / Melphalan 110, Allogeneic Stem Cell Transplantation, RIC (PID880 V1.0)Fludarabine 30 / Carmustine 200 / Melphalan 140, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1705 V1.0)Fludarabine 30 / Melphalan 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID3225 V1.0)Fludarabine 30 / TBI 2, Allogeneic Stem Cell Transplantation, NMA (PID3222 V1.0)Fludarabine 30 / Treosulfan 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabine 40 / Busulfan 3.2 / Anti-thymocyte Globulin (Rabbit) 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID881 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabine 40, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1738 V1.0)
